1
|
Alattar RA, Abdalla S, Abdallah T, Kazman R, Qadmour A, Ibrahim T, Alhariri B, Shaar SH, Bajwa A, Alimam A, Qazi R, Ben Abid F, Daghfal J, Eldeeb A, Shukri K, Elsayed A, Rustom F, Alsamawi M, Abdelmajid A, Basulto MAP, Cobian AAR, Abukhattab M, Alkhal A, Almaslamani MA, Omrani AS. Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study. J Infect Public Health 2022; 15:1061-1064. [PMID: 36087547 PMCID: PMC9420008 DOI: 10.1016/j.jiph.2022.08.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Revised: 07/21/2022] [Accepted: 08/21/2022] [Indexed: 11/18/2022] Open
Abstract
We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. The unmatched cohort included 1493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P < 0.001). Adverse events were common in both groups, but the 93.9% were Grades 1-3. Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.
Collapse
Affiliation(s)
| | | | - Tasneem Abdallah
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Rashid Kazman
- Division of Internal Medicine, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Aseelah Qadmour
- Division of Internal Medicine, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Tawheeda Ibrahim
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Bassem Alhariri
- Division of Internal Medicine, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Shahd H Shaar
- Communicable Disease Center, Hamad Medical Corporation
| | - Abeer Bajwa
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Abeir Alimam
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Rabia Qazi
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Fatma Ben Abid
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | | | - Ali Eldeeb
- Department of Clinical Imaging, Hamad Medical Corporation, Doha, Qatar
| | - Kinda Shukri
- Department of Clinical Imaging, Hamad Medical Corporation, Doha, Qatar
| | - Ahmed Elsayed
- Communicable Disease Center, Hamad Medical Corporation
| | - Fatima Rustom
- Communicable Disease Center, Hamad Medical Corporation
| | - Musaed Alsamawi
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Alaaeldin Abdelmajid
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | | | | | - Mohamed Abukhattab
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Abdullatif Alkhal
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Muna A Almaslamani
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar
| | - Ali S Omrani
- Communicable Disease Center, Hamad Medical Corporation; Division of Infectious Diseases, Department of Medicine, Hamad Medical Corporation, Doha, Qatar; Faculty of Medicine, Qatar University.
| |
Collapse
|